Emulating from the success of its 2015 sell-out show, SMi Group is delighted to announce the return of the 3rd annual conference and exhibition: Pre-Filled Syringes - East Coast, taking place on April 25th – 26th 2016 in Iselin, New Jersey, USA.

With the growing demand for biologics and ready-to-administer (RTA) syringes, recent reports have predicted the global pre-filled syringes (PFS) market to reach $6.6bn by 2020. While we have witnessed booming investments in PFS, the industry still needs to overcome a number of hurdles to commercialize this delivery platform.

Through a combination of powerful keynote addresses, topical debate and interactive workshops, Pre-Filled Syringes East Coast will once again play host to an audience of senior scientists, device manufacturers and PFS market professionals, providing a focal point to discuss the latest innovations and developments in pre-filled syringes; as well as honing in on industry challenges and regulatory compliance.

The expert speaker line-up for 2016 includes:

Stephen Barat, Executive Director, Non-Clinical & Translational Sciences, Safety Assessment & Bioanalysis, Allergan
Ravi S. Harapanhalli Ph.D., Principal, FDAPharma Consulting LLC
Mathias Romacker, Senior Director, Device Strategy, Pfizer
Dr. Paolo Mangiagalli, Senior Director, Head PFS Platform, Sanofi
Ken Wong, Deputy Director, MTech/ Process Technology – Extractables & Leachables, Sanofi Pasteur
Carsten Worsoe, Principal Scientist, CMC Analytical Support, Novo Nordisk A/S
Dr. Shawn Davis, Principal Engineer, Device Strategy, Amgen
Mohammed Umar, Principal Technical Manager, Quality Engineering, Genentech
Jason Lipman, Associate Director, Regulatory Affairs, Medical Devices & Combination Products, Janssen R&D, LLC

Event Highlights:

Discover how to eliminate extractables and leachables (E&L) through a case study driven presentation from Merck
Hear how Eli Lilly give the PFS a human touch – incorporating human factor engineering into a patient-centric device
Ensure commercial competitiveness of PFS as a drug device
Assess trends of combination products and impacts on PFS
Learn about the latest cutting edge  technological developments  in COP and sterilization to accelerate your PFS development
Exclusive post-conference workshops led by Cambridge Consultants on Human Factor Engineering and FDAPharma Cosulting LLC on CMC Considerations

For further details and to download a brochure, visit the website at www.pfsamericas.com/bioscreening

The upcoming proposed Data Protection Regulation in EU is the culmination of biobanking operations, and will constitute a new legal framework if and once passed by the European Commission. As such, SMi’s 6^th Biobanking Conference will focus on the potential changes and impacts of maintaining a sustainable biobanking infrastructure, harmonisation and interaction between biobanks across UK, Europe and the world. Our expert speaker panel comprise of industry experts from the European Commission, MHRA, UK Biobank, MedImmune, Roche, Lundbeck, Roslin Cell Sciences, and other leading European biobanks.

More information on our expert speaker panel and conference agenda will be uploaded on the website soon. http://www.bio-banking-event.com/bioscreening

SELECTBIO is pleased to announce Academic Drug Discovery 2016, which will be held on 22 - 23 March 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series. 

Attracting a global audience of researchers, academics, group leaders, directors and the global heads of leading academic and open innovation drug discovery centres, this event will explore the current challenges and opportunities faced in academic drug discovery. 

In recent years pharmaceutical companies have moved away from conducting early-stage preclinical research in-house and are instead partnering with academic institutions to pursue programmes around emerging targets. This has resulted in significant opportunities for academic-based drug discovery and development centres. 

If you work in drug discovery research you will benefit from the expert knowledge and insights provided by academic and industry leaders who are successfully demonstrating models of collaborative drug discovery.

More info: https://selectbiosciences.com/conferences/index.aspx?conf=ADD2016

In June 2015 we launched Stem Cells in Drug Discovery in Cambridge, United Kingdom to a great response! Featuring presentations from Lorenz Mayr, Joseph Wu and Chris Ward, over 90 people attended, from 9 different countries, including PhD students, Professors, Group Leaders, Directors, Global Heads and VPs of some of the world’s leading stem cell research centres.

We are looking to build the event for 2016 with an additional track, entitled Organ-on-a-Chip Europe, there will be even more talks, attendees and discussions. With human stem cells presenting a more accurate model for pre-clinical testing, this year’s agenda provides in depth insight into how stem cells are revolutionizing in vitro disease models, assay development, toxicology studies and lead generation in drug discovery.

More info: http://selectbiosciences.com/conferences/index.aspx?conf=SCDD2016

This conference brings together researchers from both academia and industry, and will discuss the development of techniques and tools implemented in High Content technologies and Phenotypic Screening applications.

Hot topics to be covered include 3D cell based screening methods, high content screening and data management, the use of model organisms and novel approaches for phenotypic screening.

Attending this event will provide you with excellent opportunities for networking with attendees from big pharmaceutical and biotech companies, academia and government, helping you to find solutions and build collaborations.

For more info: https://selectbiosciences.com/conferences/Agenda.aspx?conf=HCPS2016